Application value of NICaS in monitoring hemodynamic changes of patent ductus arteriosus in preterm infants

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200066804

Enrollment

Unknown

Registered

2022-12-19

Start date

2023-01-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patent ductus arteriosus in preterm infants

Interventions

Ibuprofen treatment group:N/A

conservative treatment group:N/A

Eligibility

Sex/Gender

All

Age

No minimum to 1 Years

Inclusion criteria

Inclusion criteria: All the preterm infants with a gestational age of 25-32 weeks who were admitted to the neonatology Department of our hospital within 1 hour after birth from January 1, 2023 to December 31, 2024 signed informed consent.

Exclusion criteria

Exclusion criteria: ?Complex congenital heart disease;? Chromosome abnormality;? Inherited metabolic diseases;? severe congenital malformation;? Incomplete clinical data.?Premature infants who died within 7 days of birth and gave up treatment.

Design outcomes

Primary

Measure	Time frame
cardiac function;haemodynamics;Liquid level;pneumorrhagia;bronchopulmonary dysplasia;necrotizing enterocolitis;acute kidney injury;intraventricular hemorrhage;	—

Countries

China

Contacts

Public ContactCuie Chen

Yiwu Maternity and Children Hospital

chencuie123456@163.com13777908806

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026